ERBB2 and gastric cancer: HER2 genomic amplification frequently appears in breast (BC) and gastric cancer (GC), with an incidence of approximately 25% and 15%, respectively; whereas it is relatively uncommon in NSCLC and CRC, with an incidence of approximately <5% [16].